2 active not recruiting. 2 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 2 | Active not recruiting 2 |
Follow Multiple System Atrophy: new trials by email Literature Review of Multiple System Atrophy trials Research Report on Multiple System Atrophy
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Trial of Amlenetug (Lu AF82422) in Participants With Multiple System Atrophy (MSA) Amlenetug, Placebo - Multiple System Atrophy | Phase 3 | Active not recruiting | H. Lundbeck A/S | 401 | 2024-12-03 | 2026-10-14 |
| Phase 3 Efficacy and Durability of Ampreloxetine for the Treatment of Symptomatic nOH in Participants With Multiple System Atrophy Ampreloxetine, Placebo - Symptomatic Neurogenic Orthostatic Hypotension, MSA - Multiple System Atrophy | Phase 3 | Active not recruiting | Theravance Biopharma | 102 | 2023-06-27 | 2025-09-05 |
Neurodegenerative Diseases (1) · Shy-Drager Syndrome (1)
Autonomic Nervous System Diseases (2) · Basal Ganglia Diseases (2) · Brain Diseases (2) · Central Nervous System Diseases (2) · Movement Disorders (2) · Nervous System Diseases (2) · Primary Dysautonomias (2) · Cardiovascular Diseases (1) · Hypotension (1) · Synucleinopathies (1) · Vascular Diseases (1)
ampreloxetine (1)
H. Lundbeck A/S (1) · Theravance Biopharma (1)
Australia (2) · Canada (2) · France (2) · Germany (2) · Italy (2) · Spain (2) · United Kingdom (2) · United States (2) · Argentina (1) · Austria (1) · Brazil (1) · Denmark (1) · Estonia (1) · Hungary (1) · Israel (1)